1Vazquez-Sequeiros E,Wang L,Urgart L.Occult lymphnode metastases as a predictor of tumor relapse in patientswith nodenegative esophageal carcinoma[J].Gastroenterology,2002,122(7):1815-1821.
3Minsky BD, Pajak T, Ginsberg RJ, et al. INT 0123 ( RTOG94-05 ) phase Ⅲ trial of combined modality therapy for esophageal cancer: high dose ( 64.8 Gy) vs standard dose ( 50.4 Gy ) radiation therapy [ J]. J Clin Oncol,2002,20 (9) : 1167-1174.
4Bhansali MS, Fujita H, Kakegawa T,et al. Pattern of recurrence after extended radical esophagectomy with three-field lymph node dissection for squamous cell carcinoma in the thoracic esophagus [J]. World J Surg,1997,21 (8) :275-282.
5Vermund H, Pories WJ, Hillard J, et al. Neoadjuvant chemoradiation therapy in patients with surgically treated esophageal cancer [ J]. Acta Oncol,2001,40(5 ) :558-565.
6$tockeld D, Tennvall J, Wagenius G, et al. A Swedish study of chemoradiation in squamous cell carcinoma of the esophagus[J]. Acta Oncol,2001,40(5 ) :566-573.
7Adelstein D J, Rice TW, Rybicki LA, et al. Does paclitaxel improve the chemoradiotherpy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy [ J]. J Clin Oncol,2000,18(5) :2032-2039.
8Lew JI, Gooding WE, Ribeiro U Jr, et al. Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma[ J ]. Arch Surg,2001,136 (6) :737-742.
9Perrachia A, Bonavina L, Ruol A, et al. Esophageal cancer: a European perspective [ J ]. Rec Res Cancer Res, 2000, 155 ( 3 ) : 119-122.
10Hammoud ZT, Kesler KA, Ferguson MK, et al. Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer[ J ]. Dis Esophagus,2006,9 (2) :69-72.
